Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
FIELD
Introduction
Official Title
Official Title
Fenofibrate Intervention and Event Lowering in Diabetes
Objective
Objective
The objective of this study is to determine the risk of fatal coronary heart disease among subjects with type 2 diabetes who are administered fenofibrate.
Timeline
Timeline
| Timeline | |
| Start Date | 01/01/1998 |
| End Date | 31/12/2005 |
| Status | Completed |
Study Description
Study Description
| Study Description | |
| Study Type | Randomized |
| Study Details | |
| Condition | Diabetes Mellitus type 2 |
| Intervention | Fenofibrate Placebo |
| Population Size | 9,795 |
Publications
Publications
The administration of fenofibrates among patients with diabetes and either low HDL or hypertension significantly decreased the rate of cardiovascular events. The reduction of cardiovascular events with the administration of fenofibrates was most pronounced among patients with hypertriglyceridemia.[1]
References
References
- ↑ Scott R, O’Brien R, Fulcher G, Pardy C, D’Emden M, Tse D; et al. (2009). “Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study”. Diabetes Care. 32 (3): 493–8. doi:10.2337/dc08-1543. PMC 2646035. PMID 18984774.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rim Halaby, M.D. [2]